Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2018

02.08.2017 | review

Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia

Characteristics and treatment outcome

verfasst von: M.D. Mirella Ampatzidou, Charikleia Kelaidi, Michael N. Dworzak, Sophia Polychronopoulou

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

At the therapeutic intersection between children and older adults, the treatment of adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) poses unique challenges due to their dismal outcome. In this brief review, we report on the biological features, clinical characteristics and treatment results of a pediatric and AYAs cohort of ALL and AML, treated in our department over a 15-year period. Additionally, we review the recent insights into disease biology, clinical, cytogenetic and molecular characteristics and differences between pediatric patients and AYAs with ALL and AML. In AYAs with ALL, most retrospective trials demonstrated a benefit of pediatric inspired regimens versus adult protocols. Translating the promising pediatric results to the AYAs subgroup, these patients can be successfully treated with risk-adjusted and minimal residual disease (MRD)-guided intensified chemotherapy, with survival rates that can surpass 70%. In AYAs the AML disease is genetically positioned more on the side of adult AML than on that of younger children, but also carries its own specific abnormalities, such as NUP98-NSD1. Toxicity may complicate all phases of treatment (induction and post-induction chemotherapy, hematopoietic stem cell transplantation-HSCT) and accounts for increased mortality, which counterbalances reduced cumulative incidence of relapse (CIR), in comparison with younger children. Intensification of supportive care while maintaining treatment intensity could further improve outcomes of AYAs with leukemia. Cooperative efforts between pediatric and adult hematologists are needed in order to further improve survival of AYAs with ALL and AML.
Literatur
2.
Zurück zum Zitat Levine SR, McNeer JS, Isakoff MS. Chalenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults. Clin Oncol Adolesc Young Adults. 2016;6:11–20. Levine SR, McNeer JS, Isakoff MS. Chalenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults. Clin Oncol Adolesc Young Adults. 2016;6:11–20.
5.
Zurück zum Zitat Ampatzidou M, Panagiotou JP, Paterakis G, et al. Childhood acute lymphoblastic leukemia: 12 years of experience, using a Berlin-Frankfurt-Munster approach, in a Greek center. Leuk Lymphoma. 2014;27:1–5, Jun. Ampatzidou M, Panagiotou JP, Paterakis G, et al. Childhood acute lymphoblastic leukemia: 12 years of experience, using a Berlin-Frankfurt-Munster approach, in a Greek center. Leuk Lymphoma. 2014;27:1–5, Jun.
6.
Zurück zum Zitat Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–89. CrossRefPubMed Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–89. CrossRefPubMed
7.
Zurück zum Zitat Ibrahim A, Ali A, Mohammed MM. Outcome of adolescents with acute lymphoblastic leukemia treated by pediatrics versus adults protocols. Adv Hematol. 2014;1–7. doi: 10.​1155/​2014/​697675 Ibrahim A, Ali A, Mohammed MM. Outcome of adolescents with acute lymphoblastic leukemia treated by pediatrics versus adults protocols. Adv Hematol. 2014;1–7. doi: 10.​1155/​2014/​697675
8.
Zurück zum Zitat Rizzari C, Putti MC, Colombini A, et al. Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment. Hematol Rep. 2014;6:5554. CrossRefPubMedPubMedCentral Rizzari C, Putti MC, Colombini A, et al. Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment. Hematol Rep. 2014;6:5554. CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Ram R, Wolach O, Vidal L, et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric inspired regimens: Systematic review and meta-analysis. Am J Hematol. 2012;87:472–8. CrossRefPubMed Ram R, Wolach O, Vidal L, et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric inspired regimens: Systematic review and meta-analysis. Am J Hematol. 2012;87:472–8. CrossRefPubMed
12.
Zurück zum Zitat Hallbook H, Gustafsson G, Smedmyr B, Swedish Adult Acute Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group. Treatment outcome in young adults and children 〉10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006;107:1551–61. CrossRefPubMed Hallbook H, Gustafsson G, Smedmyr B, Swedish Adult Acute Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group. Treatment outcome in young adults and children 〉10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006;107:1551–61. CrossRefPubMed
13.
Zurück zum Zitat Usvasalo A, Räty R, Knuutila S, et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica. 2008;93:1161–8. CrossRefPubMed Usvasalo A, Räty R, Knuutila S, et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica. 2008;93:1161–8. CrossRefPubMed
14.
Zurück zum Zitat Rytting ME, Jabbour EJ, Jorgensen JL, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91:819–23. CrossRefPubMedPubMedCentral Rytting ME, Jabbour EJ, Jorgensen JL, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91:819–23. CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Boissel N, Sender LS. Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: A focus on asparaginase. J Adolesc Young Adult Oncol. 2015;4(3):118–28. CrossRefPubMedPubMedCentral Boissel N, Sender LS. Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: A focus on asparaginase. J Adolesc Young Adult Oncol. 2015;4(3):118–28. CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12):2030–42. CrossRefPubMed Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12):2030–42. CrossRefPubMed
17.
Zurück zum Zitat Creutzig U, Zimmermann M, Reinhardt D, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122(24):3821–30. CrossRefPubMed Creutzig U, Zimmermann M, Reinhardt D, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122(24):3821–30. CrossRefPubMed
18.
Zurück zum Zitat Rubnitz JE, Onciu M, Pounds S, et al. Acute mixed lineage leukemia in children: The experience of St Jude Children’s Research Hospital. Blood. 2009;113(21):5083–9. CrossRefPubMedPubMedCentral Rubnitz JE, Onciu M, Pounds S, et al. Acute mixed lineage leukemia in children: The experience of St Jude Children’s Research Hospital. Blood. 2009;113(21):5083–9. CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children’s leukaemia working parties. Blood. 1998;92(7):2322–33. PubMed Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children’s leukaemia working parties. Blood. 1998;92(7):2322–33. PubMed
20.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. CrossRefPubMed Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. CrossRefPubMed
21.
Zurück zum Zitat Ostronoff F, Othus M, Gerbing RB, et al. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: A COG and SWOG report. Blood. 2014;124(15):2400–7. CrossRefPubMedPubMedCentral Ostronoff F, Othus M, Gerbing RB, et al. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: A COG and SWOG report. Blood. 2014;124(15):2400–7. CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat August KJ, Aplenc R, Sung L, et al. Adolescents and young adults (AYA) with acute myeloid leukemia (AML) have increased treatment-related mortality with similar outcomes – a report from the children’s oncology group trials AAML03P1 and AAML0531. Blood. 2014;124(21):3672. August KJ, Aplenc R, Sung L, et al. Adolescents and young adults (AYA) with acute myeloid leukemia (AML) have increased treatment-related mortality with similar outcomes – a report from the children’s oncology group trials AAML03P1 and AAML0531. Blood. 2014;124(21):3672.
23.
Zurück zum Zitat Creutzig U, Buechner T, Sauerland MC, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: A common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer. 2008;112(3):562–71. CrossRefPubMed Creutzig U, Buechner T, Sauerland MC, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: A common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer. 2008;112(3):562–71. CrossRefPubMed
24.
Zurück zum Zitat Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22(21):4384–93. CrossRefPubMed Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22(21):4384–93. CrossRefPubMed
25.
Zurück zum Zitat Canner J, Alonzo TA, Franklin J, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: A report from the children’s oncology group. Cancer. 2013;119(23):4162–9. CrossRefPubMedPubMedCentral Canner J, Alonzo TA, Franklin J, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: A report from the children’s oncology group. Cancer. 2013;119(23):4162–9. CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the medical research council’s 10th AML trial (MRC AML10). Blood. 1997;89(7):2311–8. PubMed Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the medical research council’s 10th AML trial (MRC AML10). Blood. 1997;89(7):2311–8. PubMed
27.
Zurück zum Zitat Tomizawa D, Watanabe T, Hanada R, et al. Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. Int J Hematol. 2015;102(3):318–26. CrossRefPubMed Tomizawa D, Watanabe T, Hanada R, et al. Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. Int J Hematol. 2015;102(3):318–26. CrossRefPubMed
28.
Zurück zum Zitat Woods WG, Franklin AR, Alonzo TA, et al. Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer. 2013;119(23):4170–9. CrossRefPubMed Woods WG, Franklin AR, Alonzo TA, et al. Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer. 2013;119(23):4170–9. CrossRefPubMed
29.
Zurück zum Zitat Majhail NS, Brazauskas R, Hassebroek A, et al. Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2012;18(6):861–73. CrossRefPubMed Majhail NS, Brazauskas R, Hassebroek A, et al. Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2012;18(6):861–73. CrossRefPubMed
30.
Zurück zum Zitat Vignon M, Andreoli A, Dhédin N, et al. Graft-Versus-Host disease in adolescents and young adults (15–24 years old) after allogeneic hematopoietic stem cell transplantation for acute leukemia in first complete remission. J Adolesc Young Adult Oncol. 2017;6(2):299–306. doi: 10.​1089/​jayao.​2016.​0060 Vignon M, Andreoli A, Dhédin N, et al. Graft-Versus-Host disease in adolescents and young adults (15–24 years old) after allogeneic hematopoietic stem cell transplantation for acute leukemia in first complete remission. J Adolesc Young Adult Oncol. 2017;6(2):299–306. doi: 10.​1089/​jayao.​2016.​0060
Metadaten
Titel
Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia
Characteristics and treatment outcome
verfasst von
M.D. Mirella Ampatzidou
Charikleia Kelaidi
Michael N. Dworzak
Sophia Polychronopoulou
Publikationsdatum
02.08.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0345-1

Weitere Artikel der Ausgabe 1/2018

memo - Magazine of European Medical Oncology 1/2018 Zur Ausgabe